36 results about "Asthma treatment" patented technology

The present invention discloses the use of SRT2104 in the preparation of a drug for treating bronchial asthma, and relates to the technical field of bronchial asthma treatment. The present invention comprehensively evaluates the activation effect of SRT2104 on airway epithelial SIRT1 and the relief effect on asthmatic airway inflammation under asthma conditions, confirms the effectiveness of SRT2104 in activating airway epithelial SIRT1 and controlling asthmatic airway inflammation under asthma conditions, and lays a foundation for the discovery of clinical medical targets and the development of drugs in the treatment of bronchial asthma.

The preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) NO.30979, the preservation date is June 17, 2024, the preservation classification is named as Lactobacillus brevis, and the preservation unit is the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms. The strain is harmless to animals and has the remarkable effects of relieving lung tissue inflammatory infiltration caused by bronchial asthma, reducing release of serum IgE and Th2 type cell factors, inhibiting activation of an NF-kappa B channel and improving allergic airway inflammation. The invention also discloses application of the strain and the thallus component thereof in preparation of drugs for preventing and treating allergic asthma.

The invention discloses an immune-engineered mitochondrial nMITO as well as a preparation method, application and an evaluation method thereof, and relates to the technical field of asthma treatment. According to the application of the immune-engineered mitochondrial nMITO in preparation of the medicine for treating asthma, through the specific immune regulation function of the nMITO, local overactivated immune cells (such as eosinophilic granulocytes and Th2 cells) of an airway are regulated in a targeted mode, abnormal release of proinflammatory factors (such as IL-4, IL-5 and IL-13) is inhibited, meanwhile, activation of an anti-inflammatory signal channel is promoted, and the anti-inflammatory effect is improved. Therefore, the steady state of the airway immune microenvironment is recovered, accurate and efficient intervention on chronic asthma inflammation is achieved, the aims of improving the treatment effect, reducing adverse reactions and reducing disease relapse are finally achieved, and a brand new technical scheme is provided for clinical treatment of asthma.

The invention discloses an asthma inhaler capable of preventing illness from slipping out of the hand, and relates to the technical field of asthma treatment, the asthma inhaler comprises a handheld inhaler and a handheld frame, one side of the upper end of the handheld inhaler is connected with an adjustable suction nozzle, the handheld frame is installed on the side, away from the adjustable suction nozzle, of the handheld inhaler, and an auxiliary loop chain is arranged below the handheld frame. According to the asthma inhaler capable of preventing the user from slipping out of the hand, the handheld frame is installed on one side of the handheld inhaler, it can be guaranteed that the user holds the handheld inhaler as much as possible by inserting fingers into the fingerstalls, and the problem that the whole handheld inhaler slips out of the hand due to unstable holding is avoided; when the handheld inhaler is used, the elastic ring is sleeved on an arm, and meanwhile, the length of the structure of the link chain can be adjusted as required, so that the handheld inhaler can be hung on the arm, the problem that the handheld inhaler falls off and is broken after being released from the hand is avoided, and the whole device is more effective, stable and safe to use.

The invention provides an atomizing bottle for treating bronchial asthma, and belongs to the technical research field of medical instruments. In order to solve the problem that liquid medicine cannot be effectively sprayed out after being pressed once after an existing dosing device is used for many times, a medicine storage bottle pressurizing mechanism and a to-be-sprayed cylinder are additionally arranged between a medicine spraying pressing rod and a medicine storage bottle; during use, the medicine spraying pressing rod pressurizes the medicine storage bottle for multiple times through the medicine storage bottle pressurizing mechanism while spraying quantitative medicine liquid in the to-be-sprayed barrel from the nozzle, so that enough medicine liquid in the medicine storage bottle is extracted into the to-be-sprayed barrel, and therefore, in emergency medicine application, it can be guaranteed that the enough and quantitative medicine liquid is sprayed out after a patient presses the medicine liquid once.

The invention discloses an application of a compound fresh bamboo juice in a guinea pig asthma model, and relates to the field of medicines, a Hartley albino guinea pig is adopted to construct an OVA induced asthma model, and the model is verified to be successfully constructed through evaluation indexes; evaluating the efficacy of the successfully constructed guinea pig asthma model by using different doses of compound fresh bamboo juice, and evaluating the efficacy of the guinea pig asthma model by scoring guinea pig capsaicin stimulation cough inducing times, alveolar lavage fluid leukocyte number, inflammatory factor content, lung tissue hydroxyproline content and behavioral signs. And evaluating the treatment effect of the compound fresh bamboo juice through Western blot detection, lung histopathology and immunofluorescence staining indexes. In a guinea pig asthma model, high-dose and medium-dose groups of the compound fresh bamboo juice can be used for remarkably reducing the number of cough, reducing the number of white blood cells in alveolar lavage fluid and the level of inflammatory factors and inhibiting pulmonary fibrosis, and a good treatment effect is shown. The results provide powerful support for potential application of the compound fresh bamboo juice in asthma treatment.

The present invention relates to a biomarker for predicting an asthma treatment response to a biological agent and a use thereof, and specifically to a method for predicting an asthma treatment effect

The utility model discloses a meridian beater for treating asthma in traditional Chinese medicine, which comprises a device body, the device body is a hollow tube, a connecting elbow is arranged on one side of the device body, a transmission mechanism is arranged in the device body and the connecting elbow, a protective sleeve is arranged at the other end of the connecting elbow, and a beating mechanism is arranged on one side of the protective sleeve. The flapping mechanism comprises a flapping hammer and a pushing block, the pushing block is arranged on one side of the flapping hammer, and sliding blocks are symmetrically arranged on the two sides of the pushing block; a spring is matched with a reset spring, a pull ring is manually loosened, and the spring and the reset spring are rebounded, so that a roller winds a traction rope until a limiting plate is clamped with the bottom of the device main body, meanwhile, the reset spring pushes a sliding block and drives a pushing block to enable a beating hammer to beat, and then the process is repeated, so that the back of the patient is beaten and beaten; meanwhile, the patient can easily and voluntarily carry out beating, knocking and force control, and the practicability of the device is enhanced.

The application belongs to the technical field of biological medicine, and particularly relates to application of an active component of chamomile in preparation of an asthma treatment preparation. The chamomile active component is prepared by the following method: chamomile is subjected to reflux extraction with ethanol as an extraction solvent to obtain an extract; the extract is purified, eluted with water and ethanol in sequence, and the eluate of ethanol is collected and dried to obtain the chamomile active component. The chamomile active component provided in the application can regulate autophagy and apoptosis through multiple targets, inhibit airway inflammation, and improve immune imbalance, and can not only effectively relieve asthma symptoms, but also reduce airway epithelial damage and inhibit airway remodeling, thereby overcoming the defects of existing drugs, such as large side effects, limited efficacy on severe and hormone-resistant asthma patients, and difficulty in reversing airway damage. The active component is derived from a natural plant, is safe, and has a good application prospect in preparation of asthma treatment drugs.

The utility model relates to the technical field of asthma treatment instruments, and discloses an asthma inhaler training detection device, which comprises an asthma inhaler, a test board and a dosage measuring structure, the dosage measuring structure is arranged on the test board, the asthma inhaler is placed on the dosage measuring structure, and the dosage of medicine in the asthma inhaler is measured through the dosage measuring structure; the respiration detection structure is arranged on the test board, and after the trainee uses the asthma inhaler, respiration is detected through the respiration detection structure; the controller is fixed on the test board and is used for recording and analyzing a detection result; and the storage structure is arranged below the test board. Compared with the prior art, the device has the advantages that the breathing frequency, rhythm and strength of a trainee can be analyzed and compared, so that the breathing mode of the trainee after using the asthma inhaler is effectively trained and improved, and the efficiency of using the asthma inhaler by the trainee is improved.

The invention discloses application of an inhibitor Acevaltrate targeting PCBP2 in preparation of a medicine for treating allergic asthma, and belongs to the technical field of biological medicine. The invention discloses application of PCBP2 as a molecular target of a drug for treating allergic asthma. The core pathological mechanism of allergic asthma is closely related to M2 polarization of macrophages, and PCBP2 positively drives the polarization process by regulating an STAT6 signal channel. Acevaltrate can specifically inhibit the biological function of PCBP2 and block M2 polarization of macrophages induced by IL-4 / IL-13, so that airway inflammation is relieved, over-generation of IgE (immunoglobulin E) is inhibited, and airway remodeling is improved. The invention further provides a pharmaceutical composition containing the Acevaltrate, a drug combination scheme of the Acevaltrate and an existing asthma treatment drug, and a drug screening system based on a PCBP2-M2 polarization axis. The technology breaks through the limitation of an existing asthma treatment target spot, realizes the trans-boundary application of Acevaltrate from an anti-tumor drug to an anti-asthma drug, provides an accurate and efficient novel treatment strategy for allergic asthma, especially refractory asthma, and has remarkable clinical transformation value and wide application prospects.

The invention discloses a bronchial asthma treatment drug based on RBX1 inhibition and application thereof, and finds that expression of RBX1 in asthma patients and disease models is up-regulated, and the expression level of RBX1 is in positive correlation with airway epithelial barrier injury and active oxygen accumulation degree, which indicates that RBX1 is a key new target for asthma treatment. On the basis of the compound Z226407860 and the compound Z4189742053, the condition that the expression of the RBX1 can be effectively inhibited is further proved. In an in-vitro model, the compounds not only significantly reduce the protein level of RBX1, but also show a good synergistic treatment effect: the compounds can effectively relieve the injury of the airway epithelial barrier and promote the integrity recovery of the barrier, and can inhibit the excessive accumulation of active oxygen at the same time, so that the asthma process is intervened from two correlative core pathological links. The research provides a solid experimental basis and a candidate compound with a clear prospect for developing a therapeutic drug which aims at bronchial asthma and has a brand new action mechanism.

The invention relates to a pharmaceutical application of ginkgo tRFs targeting PMEPA1 in treatment of asthma. The PMEPA1 is an important target which is screened out through information analysis and experimental verification and participates in asthma attack, is highly expressed in asthma and is in positive correlation with airway remodeling and airway inflammation. The tRFs adopting the gingko traditional Chinese medicine can significantly inhibit PMEPA1 and relieve collagen deposition, glycogen accumulation and airway inflammation of asthma mice. The invention prompts that PMEPA1 can become a new target for asthma pharmacy, and tRFs and pharmaceutical compositions derived from ginkgo traditional Chinese medicines can become brand new medicines for treating asthma. The medicine comprises the RNA molecule and a pharmaceutically acceptable carrier, a diluent and / or an excipient. The invention is helpful to research and development of asthma treatment medicines, and provides reference for research and development of other respiratory system disease treatment medicines.

The invention provides application of low-intensity focused ultrasound in preparation of a noninvasive asthma treatment product, and belongs to the technical field of asthma treatment. The low-intensity focused ultrasound treats the asthma by regulating and controlling the activity of the spleen nerves, the low-intensity focused ultrasound has high targeting, accuracy and durability on the asthma, and the spleen histological injury or dysfunction of adjacent organs (such as pancreas and kidneys) is not observed, so that the effectiveness and safety of the technology are proved.

The present invention provides therapeutic agents for treating human asthma through administration of an IL-6 inhibitor to humans. Representative IL-6 inhibitors in the present invention include IL-6 receptor antibodies and IL-6 antibodies. Therapeutic agents of the present invention can yield therapeutic effects in severe asthma patients who need administration of high-dose steroids and such for alleviation of symptoms, or even in patients whose symptoms are difficult to control by common treatment.

The present application relates to the field of intelligent medical auxiliary decision-making technology, and discloses a ladder treatment scheme recommendation method based on asthma control level and drug response phenotype. The present application aims to solve the problem that the existing scheme cannot identify the deep reason of uncontrolled condition, leading to blind step-up treatment. The present application excludes non-compliance interference by checking the drug execution rate, and improves the authenticity of condition assessment. The present application uses environmental exposure characteristics to adaptively correct the exhaled nitric oxide determination threshold, and eliminates the deviation of smoking on inflammation recognition. The present application combines the logic tree voting of multi-dimensional biological indicators to lock the drug response phenotype. Finally, based on the double index of condition state and phenotype, the present application locates the upgrade or transformation treatment path and generates a recommended scheme. The present application realizes the precise typing and differentiated drug administration of asthma treatment, effectively reduces the drug exposure risk of hormone-insensitive patients while ensuring the clinical efficacy.

The invention belongs to the technical field of natural medicines, and particularly provides an application of cynomorium songaricum total polysaccharide in any one or more of the following applications: (1) preparing a medicament for inhibiting parabacteroides dielsii P.disassonis; (2) preparing a medicament for preventing and / or treating chronic airway inflammatory diseases caused by parabacteroides dielsii; according to the invention, the relevance between the P.distasonis and the asthma is proposed for the first time, and a new target spot is provided for asthma treatment by inhibiting the P.distasonis; the new medicinal application of the cynomorium songaricum total polysaccharide is developed, the effect of the cynomorium songaricum total polysaccharide on inhibiting P.distans is utilized, the medicine capable of treating asthma is prepared, and the blank of targeted therapy of asthma aiming at the strain in the prior art is filled; the invention provides a new scheme different from the existing asthma treatment medicines, is expected to overcome the problems of systemic side effects or curative effect limitation and the like possibly caused by long-term use of the existing medicines, and provides a new choice for asthma treatment.

The present invention relates to a biomarker for predicting therapeutic response in asthma patients and a use thereof, and specifically, to a method for predicting therapeutic response to an anti-interleukin 4 receptor antibody (anti-IL-4R antibody), an anti-interleukin 5 antibody (anti-IL-5 antibody), or an anti-interleukin 5 receptor antibody (anti-IL-5R antibody), which is being used as a therapeutic agent for asthma, by using eicosanoids, and the like.

This disclosure relates to JAK1 pathway inhibitors and their use in the treatment of asthma.

The invention discloses an asthma lung image processing system based on lung tissue data, which relates to the technical field of medical image processing, and comprises a data acquisition module, a lung segmentation module, a feature extraction module, a visualization module, a lesion analysis module and a data storage module, the lesion analysis module is used for judging the condition of the patient according to the lung data, the lesion analysis module comprises a lung expansion unit, an airway evaluation unit and an asthma risk evaluation unit, and the lung function and the airway obstruction condition are quantitatively analyzed by evaluating the lung expansion value and the airway stenosis value of the patient and combining the actual breathing condition; the method is advantaged in that the asthma risk values are acquired, the risk threshold values are set, the asthma risk values are divided into different grades, doctors are helped to make personalized treatment schemes, subjective errors are reduced, lung health conditions of patients are accurately evaluated, and accuracy and quality of asthma treatment are improved.

A use of SRT2104 in preparation of a drug for treatment of bronchial asthma is provided, relating to the field of bronchial asthma treatment. The comprehensive analysis of the activation effect of SRT2104 on silent information regulator 1 (SIRT1) in the airway epithelium under asthma conditions and its alleviation effect on asthma airway inflammation is conducted. It is demonstrated that SRT2104 can be activated in the airway epithelium under asthma condition and effectively control asthma airway inflammation. A foundation is laid for the discovery of clinical drug targets and the development of drugs for the treatment of bronchial asthma.

The present application belongs to the technical field of biological medicine, and particularly relates to a pyruvate preparation for asthma treatment and a preparation method thereof. The pyruvate preparation comprises the following components in parts by weight: 10-12 parts of pyruvate, 10-12 parts of sodium chloride, 0.5-1 part of citric acid, and 500 parts of water for injection; and the pH of the pyruvate preparation is 6-7. The pyruvate preparation is used for daily management of asthma patients, can control the increase of inflammatory cells such as eosinophilic granulocyte, reduce inflammatory reaction, and thus achieve the purpose of inhibiting asthma. The effect of the pyruvate preparation is close to that of the same kind of hormone drug dexamethasone, and the pyruvate preparation can achieve the treatment purpose while reducing the dependence of patients on hormone drugs and side effects.

The invention belongs to the field of biological medicine, and discloses a lipid nanoparticle for delivery of miR-125a-3p by aerosol inhalation and application of the lipid nanoparticle in asthma treatment. The lipid nanoparticle comprises a carrier composed of ionized lipid, auxiliary phospholipid, cholesterol and pegylated lipid, miR-125a-3p or a functional analogue thereof encapsulated in the carrier, and an epidermal growth factor receptor (EGFR) ligand coupled to the surface of the carrier. The particles are administrated in an aerosol inhalation mode, therapeutic miRNA can be efficiently delivered to the lung, and targeting and uptake of the particles in airway epithelial cells are enhanced by means of EGFR ligands. According to the preparation, by delivering miR-125a-3p, a downstream RhoA / ROCK1 signal channel is inhibited, and airway epithelium-mesenchymal transition (EMT) is improved, so that airway inflammation, mucus secretion and remodeling are relieved, and a new strategy is provided for asthma treatment.

The invention discloses an asthma therapeutic apparatus convenient to adjust the inhalation volume, and relates to the field of asthma treatment.The asthma therapeutic apparatus comprises a machine body, a feeding pipe and a connecting guide pipe, a material mixing box is arranged on one side of the machine body, a movable cover is arranged above the material mixing box, and a material mixing assembly is arranged in the material mixing box; and the material mixing assembly comprises a driving motor, a rotating rod, a stirring rod and a shifting plate. According to the asthma therapeutic apparatus convenient to adjust the inhalation volume, by arranging the material mixing assembly and the adjusting assembly, in the using process of the asthma therapeutic apparatus, the situation that in the using process of the asthma therapeutic apparatus, medicine performance is affected due to insufficient medicine mixing is avoided, the situation that medicine precipitates when the asthma therapeutic apparatus is used is avoided, it is guaranteed that the asthma therapeutic apparatus is used smoothly, and the using efficiency of the asthma therapeutic apparatus is improved. And meanwhile, a worker can conveniently adjust the inhalation amount, so that the worker can more conveniently use the asthma therapeutic apparatus, the worker can conveniently disassemble the asthma therapeutic apparatus, and the worker can conveniently use the asthma therapeutic apparatus.

The invention discloses application of an NTA10 inhibitor Remodelin in preparation of a medicine for treating allergic asthma, and belongs to the technical field of biological medicine. The core pathological link of the allergic asthma is macrophage M2 polarization imbalance, and NAT10 serving as RNA N4-acetylcytidine modified write enzyme can drive the polarization process. Remodelin is used as an NAT10 specific inhibitor, and can be combined with an NAT10 catalytic structural domain to inhibit the activity of acetyltransferase in a targeted manner, so that an M2 polarization signal channel of macrophages induced by IL-4 / IL-13 is blocked. The invention provides an intraperitoneal injection type medicine taking Remodelin as a core active component, and in-vivo and in-vitro experiments prove that the medicine can remarkably reduce airway inflammatory cell infiltration, down-regulate inflammatory factor release, inhibit high secretion of mucus and airway remodeling, reduce the serum IgE level and effectively improve the pathology phenotype of allergic asthma. According to the invention, the asthma treatment value of the Remodelin-NAT10-macrophage M2 polarization regulation axis is disclosed for the first time, the blank of treating asthma through targeted RNA epigenetic modification is filled, and a brand new treatment scheme is provided for severe asthma.

The invention belongs to the technical field of biology, and particularly relates to application of salbutamol in preparation of a medicine for preventing and treating sepsis renal injury. The salbutamol is a salbutamol oral solution; the salbutamol can effectively relieve the sepsis renal injury and inflammation level and obviously prolong the survival time of model animals. The salbutamol is used for preventing and treating sepsis renal injury, the effect is remarkable, and sepsis renal injury indexes can be effectively improved by oral administration before operation; the side effect is small, the excitement effect on the heart is very small, and no central effect exists; the medicine is a clinical common medicine, can be atomized and inhaled in the perioperative period, and takes effect quickly; the traditional Chinese medicine composition is a common asthma treatment medicine, and can improve ventilation of patients and improve prognosis.

A use of Ganoderma fungal RNA molecules, a drug, a drug composition and a delivery carrier are provided. It has been proved that the tRFs derived from the Ganoderma traditional Chinese medicine has an obvious inhibiting effect on airway smooth muscle cell phenotype change (proliferation, abnormal secretion and the like) induced by TGF-β1 and AHR, inflammation and remodeling of asthma mice induced by Dermatophagoides pteronyssinus in the experiments of the present disclosure, which suggests that the tRFs derived from the Ganoderma traditional Chinese medicine and a pharmaceutical composition can be a brand new medicine for treating asthma. The drug comprises the RNA molecule and a pharmaceutically acceptable carrier, diluent and / or excipient. The present disclosure is helpful for the research and development of asthma treatment drugs and provides reference for the research and development of other respiratory system disease treatment drugs.

The present invention provides compounds for use in the treatment of lung diseases (particularly asthma), which bind to the cytokines IL-13 and TSLP. Treatment according to the present invention can reduce exhaled nitric oxide (FeNO) levels by at least 18 ppb compared to placebo. Treatment according to the present invention can also reduce eosinophil count, increase FEV1, and / or reduce airway inflammation.

The present application relates to an NLRP3 inflammasome activation inhibitor comprising trichospirolide A or a pharmaceutically acceptable salt thereof.

The invention discloses a mitochondrial repair factor based on NADH metabolism and application of the mitochondrial repair factor in asthma treatment, and relates to the technical field of biologication.The mitochondrial repair factor based on NADH metabolism comprises the steps of S1, functional element design and sequence optimization, S2, recombinant vector construction, S3, host cell transformation, S4, engineering bacterium multiplication culture, S5, protein purification and S6, preparation. The mitochondrial energy metabolism efficiency is directly improved by catalyzing synthesis of NADH through the NADH regeneration module; the NAD < + > transfer module maintains the steady state level of NAD < + > in mitochondria through a transmembrane transport mechanism, and cofactor depletion is avoided; according to the cofactor stabilizing module, the binding capacity of a protein structure and cofactors is enhanced, the lasting time of enzyme activity is prolonged, dynamic conformation adjustment is achieved among the modules through flexible connecting peptides, and the stability of the overall structure can be maintained while the independence of functional domains can be guaranteed.